Article and Video CATEGORIES
How do we approach acquired resistance to targeted therapies in lung cancer?
Mon, 07/08/2013 - 06:00
Please Note: While this is Still Excellent Background Info, New Treatments and Procedures Have Emerged Since this Original Post
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Please feel free to offer comments and raise questions in our
Next Previous linkPrevious PostNext Post
What's Your Story? Be a Part of the Clinical Trials Experiences Through Storytelling - Patient Perspectives 2023-24 Program
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...
Hi Tammy, Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace. I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29